Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Adarsh Vennepureddy"'
Publikováno v:
Case Reports in Medicine, Vol 2021 (2021)
Vulvar cancer accounts for about 5% of cancer of female genitalia. It may initially present as benign symptoms resulting in potential delay in diagnosis. Few cases of distant metastases to skin or breast have been reported. We present the case of a 7
Externí odkaz:
https://doaj.org/article/9105f86adf194fdda5003a89665a7c1d
Publikováno v:
Case Reports in Medicine, Vol 2021 (2021)
Case Reports in Medicine
Case Reports in Medicine
Vulvar cancer accounts for about 5% of cancer of female genitalia. It may initially present as benign symptoms resulting in potential delay in diagnosis. Few cases of distant metastases to skin or breast have been reported. We present the case of a 7
Publikováno v:
World Journal of Oncology
Treatment of lung cancer has been revolutionized with development of drugs that target key driver mutations and immune checkpoints. Until recently, it was believed that these driver mutations are mutually exclusive. However, few reports have emerged
Publikováno v:
OncoTargets and therapy
The treatment landscape for multiple myeloma (MM) is evolving with our understanding of its pathophysiology. However, given the inevitable cohort heterogeneity in salvage therapy, response to treatment and overall prognoses tend to vary widely, makin
Autor:
Terenig Terjanian, Vijeyaluxmy Motilal Nehru, Nishitha Thumallapally, Jean-Paul Atallah, Adarsh Vennepureddy
Publikováno v:
Journal of Clinical Medicine Research
Metastatic melanoma (MM) still remains as one of the most worrisome cancer known to mankind. In last two decades, treatment of melanoma took a dramatic turn with the discovery of targeted therapy which targets the mutations in mitogen-activated prote
Publikováno v:
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 25(1)
Cyclin-dependent kinase 4/6 inhibitors, which act by inhibiting progression from the G1 to S phases of the cell cycle, include palbociclib, ribociclib, abemaciclib, and trilaciclib. Palbociclib and ribociclib are currently food and drug administratio
Publikováno v:
World Journal of Oncology
Topotecan (TPT), a chemotherapeutic agent, is a topoisomerase-I inhibitor. Topoisomerase-I is a nuclear enzyme that relieves torsion strain in DNA by opening single strand breaks which helps in DNA replication. TPT inhibits this enzyme, thus preventi
Publikováno v:
Journal of Oncology Pharmacy Practice. 22:556-560
Bleomycin is a glycopeptide used as a chemotherapeutic agent for lymphomas, germ cell tumors, and pleurodesis of malignant pleural effusions. The pulmonary toxicity of bleomycin is well known while the cutaneous side effects are uncommon and varies f
Autor:
Bachar Samra, Firas Safa, Adarsh Vennepureddy, Jean Paul Atallah, Gautam Valecha, Uroosa Ibrahim
Publikováno v:
Expert review of anticancer therapy. 17(1)
Advanced non-small cell lung cancer (NSCLC) has been conventionally treated with cytotoxic chemotherapy with short-lived responses and significant toxicities. Monoclonal antibodies to programmed death-1 receptor (PD-1) and programmed death ligand 1 (
Publikováno v:
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 23(7)
Ramucirumab is a recombinant human monoclonal antibody and is used in the treatment of advanced malignancies. Its mechanism of action is by inhibiting angiogenesis in tumor cells by targeting the vascular endothelial growth factor receptor 2. United